Literature DB >> 20600306

Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives.

José M López-Novoa1, Carlos Martínez-Salgado, Ana B Rodríguez-Peña, Francisco J López-Hernández.   

Abstract

It is estimated that over 10% of the adult population in developed countries have some degree of chronic kidney disease (CKD). CKD is a progressive and irreversible deterioration of the renal excretory function that results in implementation of renal replacement therapy in the form of dialysis or renal transplant, which may also lead to death. CKD poses a growing problem to society as the incidence of the disease increases at an annual rate of 8%, and consumes up to 2% of the global health expenditure. CKD is caused by a variety of factors including diabetes, hypertension, infection, reduced blood supply to the kidneys, obstruction of the urinary tract and genetic alterations. The nephropathies associated with some of these conditions have been modeled in animals, this being crucial to understanding their pathophysiological mechanism and assessing prospective treatments at the preclinical level. This article reviews and updates the pathophysiological knowledge acquired primarily from experimental models and human studies of CKD. It also highlights the common mechanism(s) underlying the most relevant chronic nephropathies which lead to the appearance of a progressive, common renal phenotype regardless of aetiology. Based on this knowledge, a therapeutic horizon for the treatment of CKD is described. Present therapy primarily based upon renin-angiotensin inhibition, future diagnostics and therapeutic perspectives based upon anti-inflammatory, anti-fibrotic and hemodynamic approaches, new drugs targeting specific signaling pathways, and advances in gene and cell therapies, are all elaborated. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600306     DOI: 10.1016/j.pharmthera.2010.05.006

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  48 in total

Review 1.  Obstructive Sleep Apnea and Kidney Disease: A Potential Bidirectional Relationship?

Authors:  Bisher Abuyassin; Kumar Sharma; Najib T Ayas; Ismail Laher
Journal:  J Clin Sleep Med       Date:  2015-08-15       Impact factor: 4.062

Review 2.  Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies.

Authors:  António Nogueira; Maria João Pires; Paula Alexandra Oliveira
Journal:  In Vivo       Date:  2017-01-02       Impact factor: 2.155

3.  Novel Targets for Therapy of Renal Fibrosis.

Authors:  Niki Prakoura; Juliette Hadchouel; Christos Chatziantoniou
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

4.  Renoprotective effects of the novel prostaglandin EP4 receptor-selective antagonist ASP7657 in 5/6 nephrectomized chronic kidney disease rats.

Authors:  Kazuhiko Mizukami; Hiroyuki Yoshida; Eisuke Nozawa; Koichi Wada; Tohru Ugawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-12-15       Impact factor: 3.000

5.  Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2.

Authors:  Libin Ma; Hua Li; Shuchao Zhang; Xiaoling Xiong; Kean Chen; Peiwu Jiang; Kang Jiang; Gang Deng
Journal:  Int Urol Nephrol       Date:  2017-12-11       Impact factor: 2.370

6.  Serum metabolites are associated with all-cause mortality in chronic kidney disease.

Authors:  Jiun-Ruey Hu; Josef Coresh; Lesley A Inker; Andrew S Levey; Zihe Zheng; Casey M Rebholz; Adrienne Tin; Lawrence J Appel; Jingsha Chen; Mark J Sarnak; Morgan E Grams
Journal:  Kidney Int       Date:  2018-06-02       Impact factor: 10.612

7.  Quantitative characterization of glomerular fibrosis with magnetic resonance imaging: a feasibility study in a rat glomerulonephritis model.

Authors:  Christopher C Conlin; Yufeng Huang; Brian Adam Jamison Gordon; Jeff L Zhang
Journal:  Am J Physiol Renal Physiol       Date:  2018-01-03

8.  Calcitriol Ameliorates Kidney Injury Through Reducing Podocytopathy, Tubular Injury, Inflammation and Fibrosis in 5/6 Subtotal Nephrectomy Model in Rats.

Authors:  Dwi Cahyani Ratna Sari; Maulida Wijaya Putri; Tiara Putri Leksono; Nogati Chairunnisa; Gerry Nathan Reynaldi; Benhard Christopher Simanjuntak; Josephine Debora; Junaedy Yunus; Nur Arfian
Journal:  Kobe J Med Sci       Date:  2020-03-27

9.  Association of remnant cholesterol with chronic kidney disease in middle-aged and elderly Chinese: a population-based study.

Authors:  Pijun Yan; Yong Xu; Ying Miao; Xue Bai; Yuru Wu; Qian Tang; Zhihong Zhang; Jiong Yang; Qin Wan
Journal:  Acta Diabetol       Date:  2021-06-28       Impact factor: 4.280

10.  Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats.

Authors:  Mitsuhiro Kondo; Atsuo Tahara; Kazumi Hayashi; Masaki Abe; Hiroshi Inami; Takeshi Ishikawa; Hiroyuki Ito; Yuichi Tomura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-07-23       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.